Anaerobic 90Y- and 177Lu-labeling of a DOTA-conjugated nonpeptide vitronectin receptor antagonist

Bioconjugate Chemistry

Volumn 14, Issue 5, 2003, Pages 1030-1037

  Liu, Shuang ^a,b   Harris, Thomas D ^a   Ellars, Charles E ^a   Edwards, D Scott ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1H-IMIDAZOLE; ANAEROBICS; CARBOXYMETHYL; LABELINGS; NONPEPTIDE; RADIOLABELLING; RADIOLYTIC DEGRADATION; RECEPTOR ANTAGONISTS; VITRONECTIN; [CARBONYL;

RADIATION CHEMISTRY;

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; LUTETIUM; LUTETIUM 177; RADIOPHARMACEUTICAL AGENT; RECEPTOR BLOCKING AGENT; TA 138; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; YTTRIUM 90; 177LU DOTA 8 AMINOOCTANOYLBOMBESIN (7 14) AMIDE; 177LU-DOTA-8-AMINOOCTANOYLBOMBESIN (7-14)-AMIDE; BIOTIN; BOMBESIN; DOTA BIOTIN; DOTA-BIOTIN; DRUG DERIVATIVE; ORGANOMETALLIC COMPOUND; PEPTIDE FRAGMENT; RADIOISOTOPE; YTTRIUM;

ANAEROBIC METABOLISM; ARTICLE; COMPLEX FORMATION; CONJUGATE; DRUG CONJUGATION; DRUG DEGRADATION; DRUG FORMULATION; DRUG SPECIFICITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ISOTOPE LABELING; RADIOLYSIS; TECHNIQUE; THERMOSTABILITY; CHEMISTRY; DRUG ANTAGONISM; METHODOLOGY; PHARMACEUTICS;

BIOTIN; BOMBESIN; INTEGRIN ALPHAVBETA3; LUTETIUM; ORGANOMETALLIC COMPOUNDS; PEPTIDE FRAGMENTS; RADIOISOTOPES; TECHNOLOGY, PHARMACEUTICAL; YTTRIUM RADIOISOTOPES;

EID: 0141523062     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc020061h     Document Type: Article

References (58)

1. 99mTc using aminocarboxylates as co-ligands. Bioconjugate Chem. 7, 63-70.
2. 99mTc-chelator-peptide conjugates. Bioconjugate Chem. 7, 196-202.
3. 99mTc-chelator-peptide conjugates. Bioconjugate Chem. 7, 203-208.
4. 99mTc-labeling of highly potent small peptides. Bioconjuate Chem. 8, 621-636.
5. 99mTc. Bioconjugate Chem. 8, 146-154.
6. 99mTc. Bioconjuate Chem. 8, 155-160.
7. 99mTc. Bioconjuate Chem. 9, 583-595.
8. 99mTc-labeling hydrazones of a hydrazinonicotinamide conjugated cyclic peptide. Bioconjuate Chem. 10, 803-807.
9. Edwards, D. S., Liu, S., Ziegler, M. C., Harris, A. R., Crocker, A. C., Heminway, S. J., Barrett, J. A., Bridger, G. J., Abrams, M. J., and Higgins, J. D. (1999) RP463: A stabilized technetium-99m complex of a hydrazino nicotinamide conjugated chemotactic peptide for infection imaging. Bioconjuate Chem. 10, 884-891.
10. 99mTc-labeled small peptides as diagnostic radiopharmaceuticals. Chem. Rev. 99, 2235-2268.
11. Liu, S., Edwards, D. S., Harris, A. R., Heminway, S. J., and Barrett, J. A. (1999) Technetium complexes of a hydrazinonicotinamide-conjugated cyclic peptide and 2-hydrazinopyridine: Synthesis and characterization. Inorg. Chem. 38, 1326-1335.
12. 99mTc-Labeling of a hydrazinonictotinamide-conjugated LTB4 receptor antagonist useful for imaging infection. Bioconjugate Chem. 13, 881-886.
13. 99mTc-Labeling of a hydrazinonictotinamide-conjugated vitronectin receptor antagonist. Bioconjugate Chem. 12, 624-629.
14. 90Y-labeled DTPA-biomolecule conjugates. Bioconjugate Chem. 12, 84-91.
15. 111In labeled DTPA-peptide conjugates. Bioconjugate Chem. 12, 630-634.
16. 177Lu-labeling of a DOTA-conjugated vitronectin receptor antagonist for tumor therapy. Bioconjugate Chem. 12, 559-568.
17. 90Y-labeled DOTA-biomolecule conjugates using gentisic and ascorbic acid. Bioconjugate Chem. 12, 554-558.
18. 3 antagonists for tumor imaging and radiotherapy. Cancer Biother. Radiopharm., in press.
19. Folkman, J. (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med. 1, 27-31.
20. Mousa, S. A. (1998) Mechanism of angiogenesis in vascular disorders: potential therapeutic targets. Drugs Future 23, 51-60.
21. Matter, A. (2001) Tumor angiogenesis as a therapeutic target. Drug Discovery Today 6, 1005-1024.
22. Weinstat-Saslow, D., and Steeg, P. S. (1994) Angiogenesis and colonization in tumor metastatic process: basis and applied advances. FASEB 8, 401-407.
23. Blood, C. H., and Zetter, B. R. (1990) Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Biochim. Biophys. Acta 1032, 410.
24. Gasparini, G., Brooks, P. C., Biganzoli, E., Vermeulen, P. B., Bonoldi, E., Dirix, L. Y., Ranieri, G., Miceli, R., and Cheresh, D. A. (1998) Vascular integrin αvβ3: a new prognostic indicator in breast cancer. Clin. Can. Res. 4, 2625-2634.
25. Ferrara, N., and Alitalo, K. (1999) Clinical applications of angiogenic growth factors and their inhibitors. Nature Med. 5, 1359-1364.
26. Brower, V. (1999) Tumor angiogenesis-new drug on the block. Nature Biol. 17, 963-968.
27. Brooks, P. C., Montgomery, A. M. P., Rosenfeld, M., Reisenfeld, R., Hu, T., Klier, G., and Cheresh, D. A. (1994) Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79, 1157-1164.
28. Giannis, A., and Rübsam, F. (1997) Integrin antagonists and other low molecular weight compounds as inhibitors of angiogenesis: new drugs in cancer therapy. Angew. Chem., Int. Ed. Engl. 36, 588-590.
29. Haubner, R., Gratias, R., Diefenbach, B., Goodman, S. L., Jonczyk, A., and Kessler, H. (1996) Structural and functional aspect of RGD-containing cyclic pentapeptides as highly potent and selective integrin αvβ3 antagonists. J. Am. Chem. Soc. 118, 7461-7472.
30. Haubner, R., Finsinger, D., and Kessler, H. (1997) Stereoisomeric peptide libraries and peptidomimetics for designing selective inhibitors of the αvβ3 integrin for a new cancer therapy. Angew. Chem., Int. Ed. Engl. 36, 1374-1389.
31. Drake, C. J., Cheresh, D. A., and Little, C. D. (1995) An antagonist of integrin αvβ3 prevents maturation of blood vessels during embryonic neovascularization J. Cell Sci. 108, 2655-2661.
32. Allman, R., Cowburn, P., and Manson, M. (2000) In vitro and in vivo effects of a cyclic peptide with affinity for the αvβ3 integrin in human melanoma cells. Eur. J. Cancer 36, 410-422.
33. Miller, W. H., Alberts, D. P., Bhatnager, P. K., Bondinell, W. E., Callahan, J. F., Calvo, R. R., Cousins, R. D., Erhard, K. F., Heerding, D. A., Keenan, R. M., Kwon, C., Manley, P. J., Newlander, K. A., Ross, S. T., Samanen, J. M., Yuan, C. C. K., Haltiwanger, R. C., Gowen, M., Hwang, S. M., James, I. E., Lark, M. W., Rieman, D. J., Stroup, G. B., Azzarano, L. M., Slayers, K. L., Smith, B. R., Ward, K. W., Johanson, K. O., and Huffman, W. F. (2000) Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimetic. J. Med. Chem. 43, 22-26.
34. Keenan, R. M., Miller, W. H., Barton, L. S., Bondinell, W. E., Cousins, R. D., Eppley, D. F., Hwang, S. M., Kwon, C., Lago, M. A., Nguyen, T. T., Smith, B. R., Uzinskas, I. N., and Yuan, C. C. K. (1999) Orally bioavailable nonpeptide vitronectin receptor antagonists containing 2-aminopyridine arginine mimetics. Bioorg. Med. Chem. Lett. 9, 1801-1806.
35. Batt, D. G., Petraitis, J. J., Houghton, G. C., Modi, D. P., Gain, G. A., Corjay, M. H., Mousa, S. A., Bouchard, P. J., Forsythe, M. S., Harlow, P. P., Barbera, F. A., Spitz, S. M., Wexler, R. R., and Jadhav. P. K. (2000) Disubstituted indazoles as potent antagonists for the integrin αvβ3. J. Med. Chem. 43, 41-58.
36. Haubner, R., Wester, H.-J., Reuning, U., Senekowisch-Schmidtke, R., Diefenbach, B., Kessler, H., Stöcklin, G., and Schwaiger, M. (1999) Radiolabeled αvβ3 integrin antagonists: a new class of tracers for tumor imaging. J. Nucl. Med. 40, 1061-1071.
37. Van Hagen, P. M., Breeman, W. A. P., Bernard, H. F., Schaar, M., Mooij, C. M., Srinivasan, A., Schmidt, M. A., Krenning, E. P., and de Jong, M. (2000) Evaluation of a radiolabeled cyclic DTPA-RGD analogue for tumor imaging and radionuclide therapy. Int. J. Cancer (Radiat. Oncol. Invest.), 8, 186-198.
38. 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 61, 1781-1785.
39. Haubner, R., Wester, H. J., Burkhart, F., Senekowisch-Schmidtke, R., Weber, W., Goodman, S. L., Kessler, H., and Schwaiger, M. (2001) Glycolated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J. Nucl. Med. 42, 326-336.
40. Weber, W. A., Haubner, R., Vabuliene, E., Kuhnast, B., Webster, H. J., and Schwaiger, M. (2001) Tumor angiogenesis targeting using imaging agents. Quart. J. Nucl. Med. 45, 179-182.
41. Cheesman, E. H., Sworin, M. J., Liu, S., Onthank, D. C., Barrett, J. A., and Edwards, D. S. (2001) Nonpeptide vitronectin antagonists labeled with Tc-99m for imaging tumors, 222nd American Chemical Society National Meeting, Chicago, Aug 26-30, 2001, MEDI-077.
42. Harris, T. D., Kalogeropoulos, S., Bartis, J., Edwards, D. S., Liu, S., Othank, D. C., and Barrett, J. A. (2001) Radiolabeled indazole-based αvβ3 antagonists as potential tumor imaging agents. J. Labelled Compd. Radiopharm. 44 (Suppl. 1), S60-S62.
43. Moi, M. K., and Meares, C. F. (1988) The peptide way to macrocyclic bifunctional chelating agents: synthesis of 2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecane-N,N′,N″-N‴ -tetraacetic acid and study of its yttrium(III) complex. J. Am. Chem. Soc. 110, 6266-6267.
44. Li, M., and Meares, C. F. (1993) Synthesis, metal chelate stability studies, and enzyme digestion of a peptide-linked DOTA derivative and its corresponding radiolabeled immunoconjugates. Bioconjugate Chem. 4, 275-283.
45. Caravan, P., Ellison, J. J., McMurrym, T. J., and Lauffer, R. B. (1999) Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem. Rev. 99, 2293-2352, and references therein.
46. Liu, S., and Edwards, D. S. (2001) Bifunctional chelators for target specific therapeutic lanthanide radiopharmaceuticals. Bioconjugate Chem. 12, 7-34, and references therein.
47. Garrison, W. M. (1987) Reaction mechanisms in radiolysis of peptides, polypeptides, and proteins. Chem. Rev. 87, 381-398.
48. 99mTc-radiopharmaceuticals. Int. J. Appl. Radiat. Isot. 33, 1341-1344.
49. Chakrabarti, M. C., Le, N., Paik, C. H., De Graff, W. G., and Carrasquillo, J. A. (1996) Prevention of radiolysis of monoclonal antibody during labeling. J. Nucl. Med. 37, 1384-1388.
50. Salako, Q. A., O'Donnell, R. T., and DeNardo, S. J. (1998) Effects of radiolysis on yttrium-90-labeled lym-1 antibody preparations. J. Nucl. Med. 39, 667-670.
51. Lewis, M. R., Raubitschek, A., and Shively, J. E. (1994) A facile, water-soluble method for modification of proteins with DOTA. Use of elevated temperature and optimized pH to achieve high specific activity and high chelate stability in radiolabeled immunoconjugates. Bioconjugate Chem. 5, 565-576.
52. Stimmel, J. B., Stockstill, M. E., and Kull, F. C., Jr. (1995) Yttrium-90 chelation properties of tetraazatetraacetic acid macrocycles, diethylenetriaminepentaacetic acid analogues, and a novel terpyridine acyclic chelator. Bioconjugate Chem. 6, 219-225.
53. Kulis, D. L., DeNardo, S. J., DeNardo, G. L., O'Donnell, R. T., and Meares, C. F. (1998) Optimized conditions for chelation of yittrium-90-DOTA immunoconjugates. J. Nucl. Med. 39, 2105-2110.
54. Lewis, M. R., and Shively, J. E. (1998) Maleimidocycteineamido-DOTA derivatives: New reagents for radiometal chelate conjugation to antibody sulfhydryl groups undergo pH-dependent cleavage reactions. Bioconjugate Chem. 9, 72-86.
55. Stimmel, J. B., and Kull, F. C., Jr. (1998) Sammarium-153 and lutetium-177 chelation properties of selected macrocyclic and cyclic ligands. Nucl. Med. Biol. 25, 117-125.
56. Heppler, A., Froidevaux, S., Mäcke, H. R., Jermann, E., Béhé, M., Powell, P., and Hennig, M. (1999) Radiometal-labeled macrocyclic chelator-derived somatostatin analogue with superb tumor-targeting properties and potential for receptor-mediated internal therapy. Chem. Eur. J. 5, 1974-1981.
57. Liu, S. Unpublished data.
58. Nema, S., Washkuhn, R. J., and Brendel, R. J. (1997) Excipients and their use in injectable products. J. Pharm. Sci., Technol. 51, 166-171.